Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate

Review of the literature and considerations for future studies

Brit Mollenhauer, Omar Ali El-Agnaf, Katrin Marcus, Claudia Trenkwalder, Michael G. Schlossmacher

Research output: Contribution to journalReview article

83 Citations (Scopus)

Abstract

The pursuit of laboratory tests that allow for the reliable and inexpensive identification of subjects with parkinsonism represents a hot topic in translational neuroscience. This unmet need affects the counseling of presymptomatic, at-risk subjects and delays the accurate diagnosis of already symptomatic individuals. The absence of validated markers that are closely linked to the pathological disease process also compromises the objective monitoring of therapeutic interventions in clinical trials. Typical Parkinsons disease represents a heterogenous syndrome (but the majority of patients suffer from neurodegeneration) that is linked to the misprocessing of α-synuclein (α-Syn). The identification of α-Syn as a bona fide constituent of human cerebrospinal fluid and its quantification in early cross-sectional studies represent the beginning of a new chapter in Parkinsons disease research. It will determine what role, if any, cerebrospinal fluid α-Syn plays as a biomarker candidate in Lewy inclusion-positive forms of parkinsonism. This article focuses on the progress that has been made in seven recently published papers and highlights the challenges that lie ahead. We also provide specific information regarding standardized operating procedures for cerebrospinal fluid collection in PD biomarker research efforts.

Original languageEnglish
Pages (from-to)683-689
Number of pages7
JournalBiomarkers in Medicine
Volume4
Issue number5
DOIs
Publication statusPublished - Oct 2010
Externally publishedYes

Fingerprint

Synucleins
Cerebrospinal fluid
Biomarkers
Cerebrospinal Fluid
Parkinsonian Disorders
Parkinson Disease
Pathologic Processes
Neurosciences
Research
Counseling
Cross-Sectional Studies
Clinical Trials
Monitoring
Therapeutics

Keywords

  • α-synuclein
  • biomarker
  • cerebrospinal fluid
  • Parkinson's disease
  • standardized operating procedures

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery

Cite this

Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate : Review of the literature and considerations for future studies. / Mollenhauer, Brit; Ali El-Agnaf, Omar; Marcus, Katrin; Trenkwalder, Claudia; Schlossmacher, Michael G.

In: Biomarkers in Medicine, Vol. 4, No. 5, 10.2010, p. 683-689.

Research output: Contribution to journalReview article

Mollenhauer, Brit ; Ali El-Agnaf, Omar ; Marcus, Katrin ; Trenkwalder, Claudia ; Schlossmacher, Michael G. / Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate : Review of the literature and considerations for future studies. In: Biomarkers in Medicine. 2010 ; Vol. 4, No. 5. pp. 683-689.
@article{ec983f69d2a34c0e8514759c3c96984f,
title = "Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: Review of the literature and considerations for future studies",
abstract = "The pursuit of laboratory tests that allow for the reliable and inexpensive identification of subjects with parkinsonism represents a hot topic in translational neuroscience. This unmet need affects the counseling of presymptomatic, at-risk subjects and delays the accurate diagnosis of already symptomatic individuals. The absence of validated markers that are closely linked to the pathological disease process also compromises the objective monitoring of therapeutic interventions in clinical trials. Typical Parkinsons disease represents a heterogenous syndrome (but the majority of patients suffer from neurodegeneration) that is linked to the misprocessing of α-synuclein (α-Syn). The identification of α-Syn as a bona fide constituent of human cerebrospinal fluid and its quantification in early cross-sectional studies represent the beginning of a new chapter in Parkinsons disease research. It will determine what role, if any, cerebrospinal fluid α-Syn plays as a biomarker candidate in Lewy inclusion-positive forms of parkinsonism. This article focuses on the progress that has been made in seven recently published papers and highlights the challenges that lie ahead. We also provide specific information regarding standardized operating procedures for cerebrospinal fluid collection in PD biomarker research efforts.",
keywords = "α-synuclein, biomarker, cerebrospinal fluid, Parkinson's disease, standardized operating procedures",
author = "Brit Mollenhauer and {Ali El-Agnaf}, Omar and Katrin Marcus and Claudia Trenkwalder and Schlossmacher, {Michael G.}",
year = "2010",
month = "10",
doi = "10.2217/bmm.10.90",
language = "English",
volume = "4",
pages = "683--689",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate

T2 - Review of the literature and considerations for future studies

AU - Mollenhauer, Brit

AU - Ali El-Agnaf, Omar

AU - Marcus, Katrin

AU - Trenkwalder, Claudia

AU - Schlossmacher, Michael G.

PY - 2010/10

Y1 - 2010/10

N2 - The pursuit of laboratory tests that allow for the reliable and inexpensive identification of subjects with parkinsonism represents a hot topic in translational neuroscience. This unmet need affects the counseling of presymptomatic, at-risk subjects and delays the accurate diagnosis of already symptomatic individuals. The absence of validated markers that are closely linked to the pathological disease process also compromises the objective monitoring of therapeutic interventions in clinical trials. Typical Parkinsons disease represents a heterogenous syndrome (but the majority of patients suffer from neurodegeneration) that is linked to the misprocessing of α-synuclein (α-Syn). The identification of α-Syn as a bona fide constituent of human cerebrospinal fluid and its quantification in early cross-sectional studies represent the beginning of a new chapter in Parkinsons disease research. It will determine what role, if any, cerebrospinal fluid α-Syn plays as a biomarker candidate in Lewy inclusion-positive forms of parkinsonism. This article focuses on the progress that has been made in seven recently published papers and highlights the challenges that lie ahead. We also provide specific information regarding standardized operating procedures for cerebrospinal fluid collection in PD biomarker research efforts.

AB - The pursuit of laboratory tests that allow for the reliable and inexpensive identification of subjects with parkinsonism represents a hot topic in translational neuroscience. This unmet need affects the counseling of presymptomatic, at-risk subjects and delays the accurate diagnosis of already symptomatic individuals. The absence of validated markers that are closely linked to the pathological disease process also compromises the objective monitoring of therapeutic interventions in clinical trials. Typical Parkinsons disease represents a heterogenous syndrome (but the majority of patients suffer from neurodegeneration) that is linked to the misprocessing of α-synuclein (α-Syn). The identification of α-Syn as a bona fide constituent of human cerebrospinal fluid and its quantification in early cross-sectional studies represent the beginning of a new chapter in Parkinsons disease research. It will determine what role, if any, cerebrospinal fluid α-Syn plays as a biomarker candidate in Lewy inclusion-positive forms of parkinsonism. This article focuses on the progress that has been made in seven recently published papers and highlights the challenges that lie ahead. We also provide specific information regarding standardized operating procedures for cerebrospinal fluid collection in PD biomarker research efforts.

KW - α-synuclein

KW - biomarker

KW - cerebrospinal fluid

KW - Parkinson's disease

KW - standardized operating procedures

UR - http://www.scopus.com/inward/record.url?scp=77958065285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958065285&partnerID=8YFLogxK

U2 - 10.2217/bmm.10.90

DO - 10.2217/bmm.10.90

M3 - Review article

VL - 4

SP - 683

EP - 689

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 5

ER -